Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator (uPA) is important for matrix degradation and motility of cancer cells. The binding of uPA to its cell surface receptor on cancer cells is essential for effective invasion. A soluble form of urokinase receptor (suPAR) has been described in serum and ascites of ovarian cancer patients and in plasma samples of non-small cell lung cancer patients. Plasma samples from 36 head and neck squamous cell carcinoma patients and 24 healthy control persons were analysed for the presence of suPAR using enzyme-linked immunosorbent assay (ELISA) and the expression levels were correlated with clinical and histopathological data. Significantly elevated levels of suPAR in blood plasma from head and neck cancer patients were observed (p = 0.000), and the suPAR plasma levels decreased after resection of the carcinoma in 8 of 11 patients. suPAR plasma levels of cancer patients showed no significant correlations with T staging, metastasis, recurrence or differentiation stage of the tumours. The significance of suPAR plasma levels in head and neck squamous cell carcinoma patients for prognosis of the disease is discussed.